racepinephrine has been researched along with Asthma, Bronchial in 7 studies
Racepinephrine: A racemic mixture of d-epinephrine and l-epinephrine.
4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol : A catecholamine in which the aminoethyl side-chain is hydroxy-substituted at C-1 and methylated on nitrogen.
| Excerpt | Relevance | Reference |
|---|---|---|
| ", an "Asthma alert'') and to revise the indications, warnings, and directions in the labeling of products containing the ingredients ephedrine, ephedrine hydrochloride, ephedrine sulfate, epinephrine, epinephrine bitartrate, racephedrine hydrochloride, and racepinephrine hydrochloride." | 3.77 | Labeling for bronchodilators to treat asthma; cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. Final rule. ( , 2011) |
| " The highest dose used in the dose-response trials (=0." | 2.65 | Inhalation of racemic epinephrine in children with asthma. Dose-response relation and comparison with salbutamol. ( Kjellman, B; Tollig, H; Wettrell, G, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grewal, S | 1 |
| Ali, S | 1 |
| McConnell, DW | 1 |
| Vandermeer, B | 1 |
| Klassen, TP | 2 |
| Hyvärinen, MK | 1 |
| Kotaniemi-Syrjänen, A | 1 |
| Reijonen, TM | 1 |
| Korhonen, K | 1 |
| Kiviniemi, V | 1 |
| Korppi, M | 1 |
| Wiebe, K | 1 |
| Rowe, BH | 1 |
| Postma, DS | 1 |
| Jones, RO | 1 |
| Pillsbury, HC | 1 |
| Kjellman, B | 1 |
| Tollig, H | 1 |
| Wettrell, G | 1 |
| Plint, AC | 1 |
| Osmond, MH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial of Nebulized 3% Hypertonic Saline With Salbutamol in the Treatment of Acute Bronchiolitis in Pediatric Hospital[NCT02233985] | Phase 4 | 64 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| Nebulized Hypertonic Saline for Acute Bronchiolitis in the Emergency Department[NCT01247064] | Phase 4 | 62 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Prophylactic Racemic Epinephrine for the Prevention of Dysphagia in Patients Undergoing Anterior Cervical Discectomy and Fusion: A Randomized Control Trial[NCT02724761] | 90 participants (Anticipated) | Interventional | 2016-09-30 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Each patient record the time of entry and measured the total hospital stay time in hours, recording the time of discharge to determine the total stay in hours. The hospital stay will be evaluated in hours. Staying hospitalized until they had mild respiratory stage scale scores for at least 2 hrs. (NCT02233985)
Timeframe: Throughout the stay for each patient until discharge. Follow-up will be continued for a period of 30 days in which they may present readmissions, complications or adverse effects.
| Intervention | hours (Median) |
|---|---|
| Hypertonic Saline Solution 3% (SHS 3%) | 8 |
| Saline Solution 0.9% (SS 0.9%) Group | 39.3 |
It is a validated clinical scale, sufficiently reliable measure of Severity of the respiratory distress. It consists of the summation score of the sibilance / crackling parameters (the largest of them), respiratory effort, pulmonary air inlet, oxygen saturation, heart rate and breathing rate. It is stratified into 3 levels of severity: mild from 0 to 5 points, moderate from 6 to 10 and severe from 10 to 16. (NCT02233985)
Timeframe: Basal, 30 minutes after the end of the first 3 continuous nebulization sessions, at 4 hours, 8 hours and every 24 hours during the entire hospital stay
| Intervention | units on a scale (Median) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Basal | 30 minutes | 4 hours | 8 hours | 12 hours | 24 hours | 48 hours | 72 hours | 96 hours | 120 hours | 144 hours | 196 hours | |
| Hypertonic Saline Solution 3% (HSS 3%) Group | 8 | 6 | 5 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Saline Solution 0.9% (SS 0.9%) Group | 8 | 8 | 8 | 8 | 7 | 7 | 7 | 6 | 5 | 3 | 6 | 4 |
(NCT01247064)
Timeframe: Baseline and 1 hour
| Intervention | percent (Mean) |
|---|---|
| Nebulized 3% Saline | 1.1 |
| Nebulized 0.9% Normal Saline | 0.1 |
(NCT01247064)
Timeframe: 1 hour
| Intervention | percentage of participants (Number) |
|---|---|
| Nebulized 3% Saline | 50 |
| Nebulized 0.9% Normal Saline | 54.8 |
(NCT01247064)
Timeframe: 1 day
| Intervention | percentage of participants (Number) |
|---|---|
| Nebulized 3% Saline | 71 |
| Nebulized 0.9% Normal Saline | 64.5 |
The Respiratory Assessment Change Score (RACS) assesses change in respiratory status using the change in the Respiratory Distress Assessment Instrument (RDAI) and a standardized change in respiratory rate, with points being assigned by change increments of 10%. Thus, a change in respiratory rate of ≤5% from baseline counted as a change of 0 units, decrease/increase of 6% to 15% counted as improvement/deterioration of 1 unit, etc. The overall RACS is the arithmetic sum of the RDAI change and the standardized respiratory rate change between assessments with a decrease in RACS signifying improvement. (NCT01247064)
Timeframe: Baseline and 1 hour
| Intervention | units on a scale (Mean) |
|---|---|
| Nebulized 3% Saline | -1.5 |
| Nebulized 0.9% Normal Saline | -4 |
(NCT01247064)
Timeframe: Baseline and 1 hour
| Intervention | breaths per minute (Mean) |
|---|---|
| Nebulized 3% Saline | -1.8 |
| Nebulized 0.9% Normal Saline | -9.8 |
1 review available for racepinephrine and Asthma, Bronchial
| Article | Year |
|---|---|
Nebulized racemic epinephrine used in the treatment of severe asthmatic exacerbation: a case report and literature review.
Topics: Acute Disease; Adult; Asthma; Bronchodilator Agents; Epinephrine; Female; Humans; Nebulizers and Vap | 2007 |
4 trials available for racepinephrine and Asthma, Bronchial
| Article | Year |
|---|---|
A randomized trial of nebulized 3% hypertonic saline with epinephrine in the treatment of acute bronchiolitis in the emergency department.
Topics: Acute Disease; Age Factors; Asthma; Bronchiolitis, Viral; Bronchodilator Agents; Double-Blind Method | 2009 |
A randomized trial of nebulized 3% hypertonic saline with epinephrine in the treatment of acute bronchiolitis in the emergency department.
Topics: Acute Disease; Age Factors; Asthma; Bronchiolitis, Viral; Bronchodilator Agents; Double-Blind Method | 2009 |
A randomized trial of nebulized 3% hypertonic saline with epinephrine in the treatment of acute bronchiolitis in the emergency department.
Topics: Acute Disease; Age Factors; Asthma; Bronchiolitis, Viral; Bronchodilator Agents; Double-Blind Method | 2009 |
A randomized trial of nebulized 3% hypertonic saline with epinephrine in the treatment of acute bronchiolitis in the emergency department.
Topics: Acute Disease; Age Factors; Asthma; Bronchiolitis, Viral; Bronchodilator Agents; Double-Blind Method | 2009 |
Responses to inhaled bronchodilators in infancy are not linked with asthma in later childhood.
Topics: Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Child; Child, Preschool; Cross-Over S | 2006 |
Inhalation of racemic epinephrine in children with asthma. Dose-response relation and comparison with salbutamol.
Topics: Acute Disease; Administration, Intranasal; Adolescent; Albuterol; Asthma; Child; Dose-Response Relat | 1980 |
The efficacy of nebulized racemic epinephrine in children with acute asthma: a randomized, double-blind trial.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres | 2000 |
2 other studies available for racepinephrine and Asthma, Bronchial
| Article | Year |
|---|---|
Labeling for bronchodilators to treat asthma; cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. Final rule.
Topics: Anti-Allergic Agents; Anti-Asthmatic Agents; Antitussive Agents; Asthma; Bronchodilator Agents; Comm | 2011 |
Severe hospitalized croup: treatment trends and prognosis.
Topics: Aerosols; Asthma; Croup; Dexamethasone; Epinephrine; Female; Follow-Up Studies; Hospitalization; Hum | 1984 |